This Article Abstract Full Text Full Text (PDF) View Committee Members and Investigators Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (81) Citing Articles via Google Scholar Google Scholar Articles by Erdmann, E. Search for Related Content PubMed Articles by Erdmann, E. Related Collections Related Article

The Effect of Pioglitazone on Recurrent Myocardial Infarction in 2,445 Patients With Type 2 Diabetes and Previous Myocardial Infarction

Results From the PROactive (PROactive 05) Study

Erland Erdmann, MD, FESC, FACC^_*,1,_*, John A. Dormandy, FRCS, DSc^,1, Bernard Charbonnel, MD^,1, Massimo Massi-Benedetti, MD^,1, Ian K. Moules, BSc (Hons)^||,2, Allan M. Skene, PhD^¶,3 on behalf of the PROactive Investigators

^_* Medizinische Klinik III der Universität zu Köln, Köln, Germany
St. George’s Hospital, London, United Kingdom
Clinique d’Endocrinologie, Hôtel Dieu, Nantes, France
University of Perugia, Medicine and Metabolic Diseases, Perugia, Italy
^|| Takeda Global Research and Development Centre (Europe) Ltd., London, United Kingdom
^¶ Nottingham Clinical Research Ltd., Nottingham, United Kingdom.

View larger version (18K): [in this window] [in a new window] [Download PPT slide]   Figure 1 Time to Fatal/Nonfatal MI (Excluding Silent MI) Kaplan-Meier curve of the time to fatal/nonfatal myocardial infarction (MI) (excluding silent MI). The solid line represents the pioglitazone group; the dashed line represents the placebo group. CI = confidence interval; HR = hazard ratio.

View larger version (18K): [in this window] [in a new window] [Download PPT slide]   Figure 2 Time to Nonfatal MI (Excluding Silent MI), Coronary Revascularization, Acute Coronary Syndrome, or Cardiac Death (Composite Cardiac End Point) Kaplan-Meier curve of the time to nonfatal MI (excluding silent MI), coronary revascularization, acute coronary syndrome, or cardiac death (composite cardiac end point). The solid line represents the pioglitazone group; the dashed line represents the placebo group. Abbreviations as in Figure 1.